Downregulation of LKB1 suppresses Stat3 activity to promote the proliferation of esophageal carcinoma cells

Wang,Yu‑Qi; Dai,Wei‑Min; Chu,Xiang‑Yang; Yang,Bo; Zhao,Ming; Sun,Yu'e

doi:10.3892/mmr.2014.2071

Downregulation of LKB1 suppresses Stat3 activity to promote the proliferation of esophageal carcinoma cells

Authors:
- Yu‑Qi Wang
- Wei‑Min Dai
- Xiang‑Yang Chu
- Bo Yang
- Ming Zhao
- Yu'e Sun
View Affiliations

Affiliations: Department of Thoracic Surgery, General Hospital of the People's Liberation Army, Beijing 100853, P.R. China
Published online on: March 27, 2014 https://doi.org/10.3892/mmr.2014.2071
Pages: 2400-2404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor suppressor liver kinase B1 (LKB1) encodes a serine/threonine kinase. The defect in LKB1 is the primary cause of Peutz‑Jeghers syndrome (PJS). Inactivation of LKB1 by mutations or loss of LKB1 expression is associated with ovarian, lung and pancreatic cancer; however, the correlation between LKB1 and esophageal carcinoma remains unknown. Thus, quantitative PCR was performed to determine the clinical significance of LKB1 expression in 60 cases of esophageal cancer and its adjacent normal epithelium. LKB1 expression was observed to significantly downregulate the accompanying cancer progression, which was verified at the protein level by western blot analysis. Furthermore, the phosphorylated signal transducer and activator of transcription 3 (Stat3) level is reversibly associated with LKB1 expression. To determine the function of LKB1 in esophageal cancer, LKB1 expression is induced in TE1 esophageal cancer cells. The results show that LKB1 overexpression suppresses the proliferation of TE1 cells, downregulates the expression of cyclin D1 and Myc and represses Stat3 phosphorylation. Suppression of cell proliferation and cyclin D1 expression by LKB1 is fully inhibited by constitutively active Stat3C coexpression, suggesting that LKB1 inhibits esophageal cancer cell proliferation through suppression of Stat3 transaction. In conclusion, downregulation of LKB1 expression suppresses Stat3 activity that may promote tumor growth during esophageal cancer progression.

View Figures

View References

1	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
2	Knisely JP, Burtness BA and Salem RR: Surgical treatment of esophageal cancer. N Engl J Med. 348:1177–1179. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kocher HM and Tekkis PP: Surgical treatment of esophageal cancer. N Engl J Med. 348:1177–1179. 2003. View Article : Google Scholar : PubMed/NCBI
4	Hemminki A, Markie D, Tomlinson I, et al: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
5	Avizienyte E, Loukola A, Roth S, et al: LKB1 somatic mutations in sporadic tumors. Am J Pathol. 154:677–681. 1999. View Article : Google Scholar : PubMed/NCBI
6	Avizienyte E, Roth S, Loukola A, et al: Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res. 58:2087–2090. 1998.PubMed/NCBI
7	Sato N, Rosty C, Jansen M, et al: STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 159:2017–2022. 2001. View Article : Google Scholar : PubMed/NCBI
8	Wang ZJ, Churchman M, Campbell IG, et al: Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer. 80:70–72. 1999. View Article : Google Scholar : PubMed/NCBI
9	Tiainen M, Vaahtomeri K, Ylikorkala A and Mäkelä TP: Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet. 11:1497–1504. 2002. View Article : Google Scholar : PubMed/NCBI
10	Tiainen M, Ylikorkala A and Mäkelä TP: Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA. 96:9248–9251. 1999. View Article : Google Scholar : PubMed/NCBI
11	Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M and Mäkelä TP: Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 293:1323–1326. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kim DW, Chung HK, Park KC, et al: Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol. 21:3039–3049. 2007. View Article : Google Scholar
13	Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA. 101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI
14	Funamoto M, Fujio Y, Kunisada K, et al: Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem. 275:10561–10566. 2000. View Article : Google Scholar : PubMed/NCBI
15	Hutt JA, O’Rourke JP and DeWille J: Signal transducer and activator of transcription 3 activates CCAAT enhancer-binding protein delta gene transcription in G0 growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland. J Biol Chem. 275:29123–29131. 2000. View Article : Google Scholar
16	Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
17	Garcia R, Yu CL, Hudnall A, et al: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8:1267–1276. 1997.PubMed/NCBI
18	Gouilleux-Gruart V, Gouilleux F, Desaint C, et al: STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 87:1692–1697. 1996.PubMed/NCBI
19	Leu CM, Wong FH, Chang C, Huang SF and Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22:7809–7818. 2003. View Article : Google Scholar : PubMed/NCBI
20	Japanese Society for Esophageal Diseases. Guide lines for the clinical and pathologic studies on carcinoma of the esophagus. Jpn J Surg. 6:69–78. 1976. View Article : Google Scholar : PubMed/NCBI
21	Schmidt AI, Reismann M, Kübler JF, et al: Exposure to carbon dioxide and helium reduces in vitro proliferation of pediatric tumor cells. Pediatr Surg Int. 22:72–77. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hemminki A, Tomlinson I, Markie D, et al: Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet. 15:87–90. 1997. View Article : Google Scholar : PubMed/NCBI
23	Resta N, Stella A, Susca FC, et al: Two novel mutations and a new STK11/LKB1 gene isoform in Peutz-Jeghers patients. Hum Mutat. 20:78–79. 2002. View Article : Google Scholar : PubMed/NCBI
24	Wen Z, Zhong Z and Darnell JE Jr: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82:241–250. 1995. View Article : Google Scholar : PubMed/NCBI
25	Lin J, Tang H, Jin X, Jia G and Hsieh JT: p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene. 21:3082–3088. 2002. View Article : Google Scholar : PubMed/NCBI